Member Info for Globalcrossings

I remember you asking me early last month if I sold my position in CRV after that trade went horribly wrong. No, I have not.... But after doing a quite a bit research on it, and the possibility of one of their junior companies may be floated etc... I've been topping up here and there... Simply, I have a strong gut feeling about CRV.... Just read the Rns's from last month. They say it all!

Don't you already owe me a few pints!

I'm going to do it again...? I think with some of today's proceeds, I'll do another top-up of CRV... She's on the down today and a decent entry point. If everything works out with CRV according to last months 2x Rns's... I'll have a big smile on my face:)

I've already checked out BLU and the Rns did not spark an interest from me....

Yep... It actually was a rather positive Rns and the UK Govt granted them 1.9 million... That must say something about RDG...

Just after I sold my position in SVCA... The Rns for DRG popped up and I bought a position after reading the Rns a few times. I tried to give you a heads up on APC:)

It's been a nice day:)

Flying!!! Now up 63%!

Awarded 1.9 million pounds on behalf of the UK Government! DRG must be doing something positive to get that funding!

Did you catch the Rns just released for DRG? Tiny market cap and very few shares on offer... As Always DYOR!

Dropping faster than a rock!

Nice one mate:)

30 October 2013 China Growth Opportunities Limited (the "Company") Share Price Movement The Company notes the substantial increase in the price and trading volume in the shares of the Company as at the date of this announcement and wishes to state that it is not aware of any reason for such movement. For further information, please visit www.chinagrowthopportunities.com or contact: China Growth Opportunities Limited Rhys Davies + 41 (0) 796 200 215 N+1 Singer (Nomad and Broker) James Maxwell /

Check it out:)

Subsequent to that fundraising Atlantic Healthcare also announced that it had been awarded GBP1.9 million by the Technology Strategy Board (on behalf of the UK Government). Awards are granted to applicants demonstrating significant commercial and scientific potential, which reinforces our confidence in the progress made by Atlantic Healthcare to date.

Awards are granted to applicants demonstrating significant commercial and scientific potential, which reinforces our confidence in the progress made by Atlantic Healthcare to date.

Subsequent to that fundraising Atlantic Healthcare also announced that it had been awarded GBP1.9 million by the Technology Strategy Board (on behalf of the UK Government). Awards are granted to applicants demonstrating significant commercial and scientific potential, which reinforces our confidence in the progress made by Atlantic Healthcare to date. The award will contribute to the development cost of the company's core product, alicaforsen, in its forthcoming US/EU Phase 3 clinical study in pouchitis.

Check out my last post:)

Turning to our remaining private shareholding, Atlantic Healthcare plc ("Atlantic Healthcare"), we are happy to report that the company continues to progress very well. In March 2013 we announced that the company had completed a fundraising which increased the holding value of our investment in the company. Subsequent to that fundraising Atlantic Healthcare also announced that it had been awarded GBP1.9 million by the Technology Strategy Board (on behalf of the UK Government). Awards are granted to applicants demonstrating significant commercial and scientific potential, which reinforces our confidence in the progress made by Atlantic Healthcare to date. The award will contribute to the development cost of the company's core product, alicaforsen, in its forthcoming US/EU Phase 3 clinical study in pouchitis. In addition alicaforsen has been granted orphan designation in Europe and the United States for treatment of this disease, reflecting the fact that alicaforsen addresses an area of high unmet medical need. We shall continue to update shareholders on progress. Finally, we note the reduced proportion of listed shareholdings and hence liquidity within the portfolio. This reflects disappointing results from a number of AIM investments alongside the cost of maintaining Draganfly's AIM quoted status. The Board believes that the company is able to meet its financial obligations for the next 12 months, and subject to the performance of the unquoted holdings, an even longer period. However there is uncertainty and this has been raised in the notes to the accounts and the Audit Report. We are reviewing strategies which we hope can provide improved scale and investment performance, and your Board will be updating investors in due course. May I take this opportunity to thank investors for their support. Edward Bayman

30 October 2013 Draganfly Investments Limited ("Draganfly" or the "Company") Directors' report and audited financial statements for the year ended 30 April 2013 Chairman's Statement For the year ended 30 April 2013 During the 12 months under review net assets have decreased from 0.67 pence per share to 0.65 pence per share. Whilst this outcome represents a negligible change in Net Asset Value, the composition of the portfolio has altered materially. We have sold a substantial proportion of our quoted positions during the period, and have also sold our entire position in Immedia Group Plc since the period end. This leaves the portfolio with only two quoted shareholdings, ASX listed Royal Resources Limited and AIM listed Strategic Minerals PLC. Turning to our remaining private shareholding, Atlantic Healthcare plc ("Atlantic Healthcare"), we are happy to report that the company continues to progress very well. In March 2013 we announced that the company had completed a fundraising which increased the holding value of our investment in the company. Subsequent to that fundraising Atlantic Healthcare also announced that it had been awarded GBP1.9 million by the Technology Strategy Board (on behalf of the UK Government). Awards are granted to applicants demonstrating significant commercial and scientific potential, which reinforces our confidence in the progress made by Atlantic Healthcare to date. The award will contribute to the development cost of the company's core product, alicaforsen, in its forthcoming US/EU Phase 3 clinical study in pouchitis. In addition alicaforsen has been granted orphan designation in Europe and the United States for treatment of this disease, reflecting the fact that alicaforsen addresses an area of high unmet medical need. We shall continue to update shareholders on progress. Finally, we note the reduced proportion of listed shareholdings and hence liquidity within the portfolio. This reflects disappointing results from a number of AIM investments alongside the cost of maintaining Draganfly's AIM quoted status. The Board believes that the company is able to meet its financial obligations for the next 12 months, and subject to the performance of the unquoted holdings, an even longer period. However there is uncertainty and this has been raised in the notes to the accounts and the Audit Report. We are reviewing strategies which we hope can provide improved scale and investment performance, and your Board will be updating investors in due course. May I take this opportunity to thank investors for their support. Edward Bayman Chairman